Journal of Clinical Oncology

Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Journal of Clinical Oncology

Luchia Andemicael, Hewitt Chang, Moshiur Mekhail Anwar, Kelly Bauer, John Gordan, Jamese Johnson, Bridget P Keenan, Alan P. Venook, Chia-Ching Jackie Wang, Karen Zhang, Lawrence Fong, Robin Kate Kelley, Mary Uan-Sian Feng

A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).

Journal of Clinical Oncology

Hewitt Chang, Luchia Andemicael, Moshiur Mekhail Anwar, John Gordan, Jamese Johnson, Bridget P Keenan, Robin Kate Kelley, Andrew H. Ko, Katherine Van Loon, Alan P. Venook, Lawrence Fong, Melody Ju Xu, Mary Uan-Sian Feng

Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Journal of Clinical Oncology

Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology

Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman

Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials.

Journal of Clinical Oncology

Zoe E. Quandt, Vanessa Hill, Joe E. Dib, Jason Burian, Sapir Tessler, Abdul Rafeh Naqash, Mark S Anderson, Megan Othus, Elad Sharon

Evaluating survival following severe immune-related adverse events requiring hospitalization.

Journal of Clinical Oncology

Francis Wright, Daniel Myung Kim, Jordyn Silverstein, Michelle Wang, Kimberly de Dios, Arabella Young, Zoe E. Quandt, Sam Brondfield

Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology

Andrea Grace Bocobo, Renee Wang, Spencer Behr, Julia C. Carnevale, Pelin Cinar, Eric Andrew Collisson, Lawrence Fong, Bridget P Keenan, Wesley Allen Kidder, Andrew H. Ko, Kanti Pallav Kolli, Megan Kennedy, Angela Laffan, Sorbarikor Piawah, Marin Pollak, Gabriel Schwartz, Julia Whitman, Li Zhang, Katherine Van Loon, Chloe Evelyn Atreya

Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial.

Journal of Clinical Oncology

Robin Kate Kelley, Paige M. Bracci, Bridget Keenan, Spencer Behr, Faaiz Ibrahim, Marin Pollak, John Gordan, Andrew H. Ko, Katherine Van Loon, Chloe Evelyn Atreya, Pelin Cinar, Alan P. Venook, Lawrence Fong

Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.

Journal of Clinical Oncology

Mary Kathryn Abel, Michelle E. Melisko, Hope S. Rugo, Amy Jo Chien, Italia Diaz, Julia K. Levine, Ann Griffin, Joseph McGuire, Laura Esserman, Hala Borno, Rita A. Mukhtar

The marginal diagnostic benefit of pancreatic cancer molecular profiling after germline testing.

Journal of Clinical Oncology

Evan Justin Walker, Amie Blanco, Julia C. Carnevale, Pelin Cinar, Eric Andrew Collisson, Margaret A. Tempero, Andrew H. Ko

Pages